Menlo Security Joins VMware SD-WAN Security Technology Partner Program to Deliver Secure Cloud Transformation
6.11.2019 11:00:00 EET | Business Wire | Press release
Menlo Security, a leader in cloud security, today announced a new integration with VMware SD-WAN by VeloCloud, which offers the industry’s most flexible enterprise SD-WAN architecture. The solution delivers Secure Cloud Transformation, which optimizes and secures local Internet breakouts and enables global low latency access to the Internet and business-critical SaaS applications for an enterprise’s entire local and remote workforce. The integration is available immediately to all VMware SD-WAN customers.
“Menlo Security helps some of the largest enterprises and government agencies in the world transform their infrastructure and move security to the cloud, while maintaining global visibility and control of their traffic,” said Poornima DeBolle, chief product officer at Menlo Security. “VMware SD-WAN by VeloCloud combined with the Menlo Security Cloud Platform powered by isolation redefines security and provides the industry’s most secure solution for Internet and SaaS applications.”
"VMware SD-WAN provides the optimal combination of intrinsic security in the multi-service Edge for corporate traffic as well as SD-WAN optimized access via our Network of Clouds Service gateways to the innovative Menlo Security Cloud Platform powered by isolation," said Steve Woo, senior director of product management at VMware. "Access to cloud and SaaS applications is automatically provisioned, optimized for performance and secured with VMware SD-WAN and Menlo Security Cloud Platform."
VMware SD-WAN customers have simplified their branch office networking and optimized application performance over the Internet. Secure Cloud Transformation, powered by isolation, allows companies to improve security control and visibility across their SD-WAN deployment. Moving to SD-WAN requires an enterprise to move their security to the cloud since user traffic is not backhauled to a central security stack. Menlo Security Cloud Platform allows users to go directly to the Internet while ensuring consistent and robust security controls, whether they are connecting from HQ, remote offices, on the road or in a coffee shop.
Menlo Security’s customers include some of the largest enterprises and government agencies. The company’s cloud security platform currently processes more than 500 million web requests per day. Among the company’s customers are seven of the 10 largest banks, four of the five largest credit-card issuers and some of the largest energy and transportation companies in the world.
For more information, please send an email to ask@menlosecurity.com.
Additional Resources
- Secure Cloud Transformation
- Menlo Security Secure Web Gateway
- Definitive Guide to Internet Isolation
VMware and SD-WAN by VeloCloud are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions.
About Menlo Security
Menlo Security protects organizations from cyber attacks by eliminating the threat of malware from the web, documents and email. Its cloud-based Isolation Secure Web Gateway scales to provide comprehensive protection across enterprises of any size, without requiring endpoint software or impacting the end user-experience. The company was named a Visionary in the Gartner Magic Quadrant for the Secure Web Gateway. Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC and JP Morgan Chase. Menlo Security is headquartered in Palo Alto, California. For more information, visit https://www.menlosecurity.com or ask@menlosecurity.com
VMware, and VeloCloud are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005218/en/
Contact information
Lexie Janney
Merritt Group for Menlo Security
703.390.1531
janney@merrittgrp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release
Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
